Back to Authors

Ma, Shuo

Mayo Clinic

Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Citations 1

NCCN Guidelines® Insights: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Version 2.2026
Wierda, William G., Brown, Jennifer, Abramson, Jeremy, Bociek, Greg, Boyer, Daniel F. , Cortese, Matthew J , Cripe, Larry D., D’Angelo, Christopher R. , Darnell, Elijah P., Davis, Randall S. , Eradat, Herbert, Esteghamat, Naseem , Fitzgerald, Lindsey , Fletcher, Christopher D., Gaballa, Sameh , Kamdar, Manali, Kipps, Thomas J., Ma, Shuo, Nakhoda, Shazia, Schorr, Andrew, Schuster, Stephen, Seshadri, Madhav, Shanafelt, T., Ujjani, Chaitra, Wagner-Johnston, Nina, Woyach, Jennifer A. , Dwyer, Mary, Sundar, Hema, Shanafelt, Tait D. , Shanafelt, Tait D , Wierda, William G. , Abramson, Jeremy S. , Awan, Farrukh T. , Huntington, Scott F. , Kahl, Brad S. , Kamdar, Manali , Kipps, Thomas J. , Ma, Shuo, Mosse, Claudio A. , Nakhoda, Shazia , Parikh, Sameer A. , Riedell, Peter A. , Seshadri, Madhav , Siddiqi, Tanya , Sitlinger, Andrea Phillips , Thompson, Meghan C , Ujjani, Chaitra S. , Wagner‐Johnston, Nina D. , Dwyer, Mary A.

Journal of the National Comprehensive Cancer Network | March 12, 2026 | Volume: 24 | Issue: 3 | Pages: 68-80

10.6004/jnccn.2026.0012 Get It

Bruton tyrosine kinase inhibitors (BTKis) and BCL2 inhibitor (BCL2i)–containing regimens significantly improve survival outcomes in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL). Results from randomized clinical trials have demonstrated that time-limited treatment with BCL2i-containing regimens resulted in higher rates of undetectable measurable residual disease (uMRD) than BTKi monotherapy or chemoimmunotherapy (CIT). Pirtobrutinib (a noncovalent BTKi) and lisocabtagene maraleucel (CD19-directed CAR T-cell therapy) are newer options for relapsed or refractory disease after prior therapy with BTKi and BCL2i-contining regimens. Histologic transformation of CLL/SLL to diffuse large B-cell lymphoma (Richter transformation) is associated with a poor prognosis. Molecular analysis to determine whether there is clonal relationship between CLL/SLL and transformed diffuse large B-cell lymphoma is useful to select an appropriate treatment option. These NCCN Guideline Insights highlight significant updates to the NCCN Guidelines for the treatment of CLL/SLL and Richter transformation.